Corrects company name in headline
** Shares of Argenica Therapeutics AGN.AX rise 3.1% to A$0.675, their highest level since Jan. 21
** Clinical drug developer announces that the Data Safety Monitoring Board recommends that trials for its drug ARG-007, continue without any changes
** ARG-007 is a drug to reduce the death of brain tissue after a stroke
** 132,174 shares change hands, 1.4 times the 30-day average
** Stock up 7.9% this month, including session's moves
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.